TIDMAVCT

Avacta Group PLC

16 October 2017

Hardman Res.: R&D accelerated to advance assets

R&D accelerated to advance assets - Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which dominates the drug industry, despite its limitations. Avacta has made considerable progress towards its strategic goal to be ready to enter first-in-man Affimer trials by the end of 2019. Recent results highlighted significant progress made in its in-house therapeutic programmes with the first in-vivo studies showing safety, tolerability and efficacy of an Affimer. This adds to the de-risking of Affimer technology and attracting potential partners.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/avacta-documents/16.10.17-r-d-accelerated-to-advance-assets.pdf

 
 To contact us:    Contacts:           +44 20 7194 7622 
 Hardman & Co      Dr Martin Hall      mh@hardmanandco.com 
 35 New Broad      Dr Dorothea Hill    dmh@hardmanandco.com 
  Street 
 London            Dr Gregoire Pave    gp@hardmanandco.com 
 EC2M 1NH 
 Follow us on      @HardmanandCo       www.hardmanandco.com 
  Twitter

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAFFUSUMFWSEDS

(END) Dow Jones Newswires

October 16, 2017 05:42 ET (09:42 GMT)

Avacta (LSE:AVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Avacta Charts.
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Avacta Charts.